Clinical OMICs - Issue 3 - (Page 15)

Clinical OMICs NEW PRODUCTS Prostate Cancer Blood Test The Prostate Health Index (phi), a noninvasive blood test reportedly three times more specific in detecting prostate cancer than prostate-specific antigen (PSA), is now available in the U.S. through the national clinical reference lab Innovative Diagnostics Laboratory. The phi test uses three different PSA markers (PSA, freePSA and p2PSA) as part of an algorithm to determine the probability of cancer in patients with elevated PSA levels, reducing the need for many men to undergo a biopsy in order to achieve a reliable diagnosis. Beckman Coulter www.beckmancoulter.com Mycoplasma DNA Reference Materials Quantitative mycoplasma genomic DNA has been prepared as Certified Reference Materials for inclusivity/exclusivity testing, establishing limits of detection, and validating or comparing test methods. These nucleic acid preparations were isolated from strains most frequently associated with cell culture contamination, and were quantified for genome copy number using digital PCR-based technology. They are designed for PCRbased detection of mycoplasma in cell culture, animal sera, and other raw materials and support quality control products such as the Universal Mycoplasma Detection Kit and 10 titered mycoplasma reference strains. ATCC www.atcc.org HPV Test for Cervical Cancer Screening The cobas HPV Test can be used instead of Pap in first-line primary screening for cervical cancer in women 25 and older. The assay can provide specific genotyping information for HPV 16 and 18 (the highest-risk types), while simultaneously reporting the 12 other high-risk HPV types as a pooled result in one run from one patient sample. The test is performed on the cobas 4800 System. Roche www.roche.com www.clinicalomics.com Multi-Analyte Test for Autoimmune Epilepsy A suite of new testing services is now available from the Athena Diagnostics specialty neurology business that are designed to help physicians more reliably and quickly diagnose the cause of several forms of epilepsy in adults and children. These lab-developed tests are based on next-generation gene sequencing and neuroimmunological testing and include a multi-analyte test panel to analyze five antibodies associated with autoimmune epilepsy, which accounts for up to 10% of epilepsy cases. Quest Diagnostics www.questdiagnostics.com May 15, 2014 Clinical OMICs 15 http://www.beckmancoulter.com http://www.atcc.org http://www.questdiagnostics.com http://www.roche.com http://www.clinicalomics.com

Table of Contents for the Digital Edition of Clinical OMICs - Issue 3

Contents

Clinical OMICs - Issue 3